Targeting gut S. aureofaciens Tü117 serves as a new potential therapeutic intervention for the prevention and treatment of hypertension.

Currently, the regulation of specific gut microbial metabolism for the development and/or treatment of hypertension remains largely unexplored. Here, we show that α-lipomycin, produced by Streptomyces aureofaciens (S. aureofaciens) Tü117, is upregulated in the serum of high-salt diet (HSD) mice and patients with essential hypertension. α-lipomycin causes vasodilation impairment involving transient receptor potential vanilloid 4 (TRPV4)-mediated nitric oxide and endothelium-derived hyperpolarizing factor pathways in mice. We also find that Lactobacillus plantarum (L. plantarum) CCFM639 attenuates the increase in blood pressure (BP) potentially through inhibiting the proliferation of S. aureofaciens Tü117 in mice. An exploratory intervention trial indicates that L. plantarum CCFM639 supplementation reduces BPs in subjects newly diagnosed with pre-hypertension or stage 1 hypertension without antihypertensive medication. Our findings provide evidence for a role of S. aureofaciens Tü117-associated α-lipomycin elevation in the pathogenesis of HSD-induced hypertension, highlighting that targeting gut bacteria serves as a new therapeutic intervention for hypertension.
Competing Interests: Declaration of interests X.M., T.Z., and Z.W. have filed a patent to the State Intellectual Property Office of P.R. China (202110177670.0 and PCT/CN2021/078832). X.M., T.Z., Z.W., M. Guo, and X.Q.Z. have been granted two patents by the State Intellectual Property Office of P.R. China (ZL202110274048.1 and ZL202110400785.1). W.C. and Q.Z. have been granted a patent by the State Intellectual Property Office of P.R. China (ZL201510090228.9).
(Copyright © 2025 Elsevier Inc. All rights reserved.)